- Home
- CTNM vs AXR Comparison
CTNM vs AXR Comparison
Compare CTNM & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- AXR
- Stock Information
- Founded
- CTNM 2009
- AXR 1961
- Country
- CTNM United States
- AXR United States
- Employees
- CTNM N/A
- AXR N/A
- Industry
- CTNM
- AXR Homebuilding
- Sector
- CTNM
- AXR Real Estate
- Exchange
- CTNM Nasdaq
- AXR Nasdaq
- Market Cap
- CTNM 114.1M
- AXR 110.0M
- IPO Year
- CTNM 2024
- AXR N/A
- Fundamental
- Price
- CTNM $3.51
- AXR $23.40
- Analyst Decision
- CTNM Strong Buy
- AXR
- Analyst Count
- CTNM 4
- AXR 0
- Target Price
- CTNM $23.75
- AXR N/A
- AVG Volume (30 Days)
- CTNM 83.1K
- AXR 10.9K
- Earning Date
- CTNM 05-14-2025
- AXR 03-07-2025
- Dividend Yield
- CTNM N/A
- AXR N/A
- EPS Growth
- CTNM N/A
- AXR 472.07
- EPS
- CTNM N/A
- AXR 2.41
- Revenue
- CTNM N/A
- AXR $58,052,000.00
- Revenue This Year
- CTNM N/A
- AXR N/A
- Revenue Next Year
- CTNM N/A
- AXR N/A
- P/E Ratio
- CTNM N/A
- AXR $9.81
- Revenue Growth
- CTNM N/A
- AXR 30.35
- 52 Week Low
- CTNM $3.69
- AXR $15.88
- 52 Week High
- CTNM $22.00
- AXR $39.67
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- AXR 57.19
- Support Level
- CTNM N/A
- AXR $20.95
- Resistance Level
- CTNM N/A
- AXR $22.31
- Average True Range (ATR)
- CTNM 0.00
- AXR 1.05
- MACD
- CTNM 0.00
- AXR 0.07
- Stochastic Oscillator
- CTNM 0.00
- AXR 72.59
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve the obtaining of approvals and the sale of both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.